Evidence map›Paper›PMID 33906643›Full record

ArticleBMC infectious diseases2021

Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.

Machiko Umemura, Goki Suda, Shihori Tsukamoto, Ko Ebata, Shinjiro Takahash, Takashi Sasaki, Sae Nakajima, Koji Hirata, Mariko Ozasa, Masatoshi Takano and 2 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Machiko Umemura *Sapporo Hokuyu Hospital, Sapporo, Hokkaido, Japan.
Goki Suda *Sapporo Hokuyu Hospital, Sapporo, Hokkaido, Japan. gsudgast@pop.med.hokudai.ac.jp.ORCID http://orcid.org/0000-0003-0098-9106
Shihori TsukamotoSapporo Hokuyu Hospital, Sapporo, Hokkaido, Japan.
Ko EbataSapporo Hokuyu Hospital, Sapporo, Hokkaido, Japan.
Shinjiro TakahashSapporo Hokuyu Hospital, Sapporo, Hokkaido, Japan.
Takashi SasakiSapporo Hokuyu Hospital, Sapporo, Hokkaido, Japan.
Sae NakajimaSapporo Hokuyu Hospital, Sapporo, Hokkaido, Japan.
Koji HirataSapporo Hokuyu Hospital, Sapporo, Hokkaido, Japan.
Mariko OzasaSapporo Hokuyu Hospital, Sapporo, Hokkaido, Japan.
Masatoshi TakanoSapporo Hokuyu Hospital, Sapporo, Hokkaido, Japan.
Masaki KatagiriSapporo Hokuyu Hospital, Sapporo, Hokkaido, Japan.
Naoya SakamotoDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
Sapporo Hokuyu Hospital · JPHokkaido University · JPHokkaido University of Science · JP

Funding

Japan Agency for Medical Research and Development JP20fk0210072, JP20fk0210047
6 · The paper itself

Abstract

backgroundIn patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. However, appropriate therapeutic strategies for managing hepatitis C flare during R-CHOP have not been established, and this issue is complicated by conflicting results regarding the use of direct-acting antivirals in patients with uncontrolled malignancies. CASE PRESENTATION: We report the first case of effective and safe treatment with on-demand 8-week glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in a patient with diffuse large B-cell lymphoma (DLBCL). The patient completed five additional courses of R-CHOP without hepatic toxicity. A complete response of DLBCL and a sustained virological response were observed at 24 weeks after glecaprevir and pibrentasvir completion.

conclusionOn-demand, direct-acting antivirals could be a novel strategy for managing hepatitis C flare during R-CHOP.

Indexed as

Aminoisobutyric AcidsAntineoplastic Combined Chemotherapy ProtocolsAntiviral AgentsBenzimidazolesCyclophosphamideCyclopropanesDoxorubicinGenotypeHepacivirusHepatitis CHumansLactams, MacrocyclicLeucineLymphoma, Large B-Cell, DiffuseMaleMiddle AgedAminoisobutyric AcidsAntiviral AgentsBenzimidazolesCyclophosphamideCyclopropanesDoxorubicinglecaprevirLactams, MacrocyclicLeucinepibrentasvirPrednisoneProlinePyrrolidinesQuinoxalinesR-CHOP protocolRituximabRNA, ViralSulfonamidesVincristineDirect-acting antiviral, hepatitis C flareGlecaprevirHepatitis C virusPibrentasvir

Identifiers

PMID33906643
PMCPMC8077834
OpenAlexW3159458215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.